{
    "response": "**Overall Treatment Decision:** Yes.\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Hospital admission with frequent neurological observations and fall precautions\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Risk of neurological deterioration Unsteady gait with spasticity Facilitates urgent imaging and multidisciplinary input\n\n*   **Treatment:** Corneal protection (lubricating drops/ointment; eye patch if exposure)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Severe left ptosis/ophthalmoplegia risks exposure keratopathy Symptomatic relief of diplopia if present\n\n*   **Treatment:** Mechanical venous thromboembolism prophylaxis (intermittent pneumatic compression)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility from spastic paraparesis Avoids anticoagulation before excluding aneurysm\n\n*   **Treatment:** High-dose intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start after CTA/MRA excludes aneurysm and infection Treats suspected inflammatory demyelinating relapse Best efficacy when started within 14 days of relapse\n\n*   **Treatment:** Endovascular coiling or surgical clipping of a posterior communicating artery aneurysm (if confirmed)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate immediately once aneurysm is identified on urgent angiography Prevents rupture and treats compressive third-nerve palsy\n\n*   **Treatment:** Physiotherapy and gait/balance rehabilitation\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Improves mobility and reduces falls Addresses spasticity and ataxic gait early\n\n*   **Treatment:** Oral baclofen titration for spasticity\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Introduce after acute diagnostic phase Adjust based on response and side effects\n\n*   **Treatment:** Long-term disease-modifying therapy for MS (agent based on MRI/CSF and risk profile, e.g., ocrelizumab or natalizumab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only after diagnostic confirmation and exclusion of mimics Requires baseline screening and counselling\n\n*   **Treatment:** Proton pump inhibitor and bone protection while on high-dose steroids\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Begin when steroids are initiated Reduces gastrointestinal and bone-related adverse effects\n\n\ntreatments = [{\"treatment\": \"Hospital admission with frequent neurological observations and fall precautions\", \"timing\": \"Start Now\", \"reasons\": [\"Risk of neurological deterioration\", \"Unsteady gait with spasticity\", \"Facilitates urgent imaging and multidisciplinary input\"]}, {\"treatment\": \"Corneal protection (lubricating drops/ointment; eye patch if exposure)\", \"timing\": \"Start Now\", \"reasons\": [\"Severe left ptosis/ophthalmoplegia risks exposure keratopathy\", \"Symptomatic relief of diplopia if present\"]}, {\"treatment\": \"Mechanical venous thromboembolism prophylaxis (intermittent pneumatic compression)\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility from spastic paraparesis\", \"Avoids anticoagulation before excluding aneurysm\"]}, {\"treatment\": \"High-dose intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Delay\", \"reasons\": [\"Start after CTA/MRA excludes aneurysm and infection\", \"Treats suspected inflammatory demyelinating relapse\", \"Best efficacy when started within 14 days of relapse\"]}, {\"treatment\": \"Endovascular coiling or surgical clipping of a posterior communicating artery aneurysm (if confirmed)\", \"timing\": \"Delay\", \"reasons\": [\"Initiate immediately once aneurysm is identified on urgent angiography\", \"Prevents rupture and treats compressive third-nerve palsy\"]}, {\"treatment\": \"Physiotherapy and gait/balance rehabilitation\", \"timing\": \"Start Now\", \"reasons\": [\"Improves mobility and reduces falls\", \"Addresses spasticity and ataxic gait early\"]}, {\"treatment\": \"Oral baclofen titration for spasticity\", \"timing\": \"Delay\", \"reasons\": [\"Introduce after acute diagnostic phase\", \"Adjust based on response and side effects\"]}, {\"treatment\": \"Long-term disease-modifying therapy for MS (agent based on MRI/CSF and risk profile, e.g., ocrelizumab or natalizumab)\", \"timing\": \"Delay\", \"reasons\": [\"Start only after diagnostic confirmation and exclusion of mimics\", \"Requires baseline screening and counselling\"]}, {\"treatment\": \"Proton pump inhibitor and bone protection while on high-dose steroids\", \"timing\": \"Delay\", \"reasons\": [\"Begin when steroids are initiated\", \"Reduces gastrointestinal and bone-related adverse effects\"]}]"
}